Advances in treatment strategies have increasingly focused on molecular characteristics, such as HER2 activation, estrogen receptor (ER) and progesterone receptor (PR) expression, gene mutations, and tumor microenvironment markers [58]. The gene discussed is PGR; the disease is neoplasm.